CA2613970C - Chimeric vaccine for haemophilus influenzae-induced disease - Google Patents

Chimeric vaccine for haemophilus influenzae-induced disease Download PDF

Info

Publication number
CA2613970C
CA2613970C CA2613970A CA2613970A CA2613970C CA 2613970 C CA2613970 C CA 2613970C CA 2613970 A CA2613970 A CA 2613970A CA 2613970 A CA2613970 A CA 2613970A CA 2613970 C CA2613970 C CA 2613970C
Authority
CA
Canada
Prior art keywords
seq
nthi
protein
infection
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2613970A
Other languages
English (en)
French (fr)
Other versions
CA2613970A1 (en
Inventor
Lauren O. Bakaletz
Robert S. Munson, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Children's Hospital
Original Assignee
Nationwide Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Children's Hospital filed Critical Nationwide Children's Hospital
Publication of CA2613970A1 publication Critical patent/CA2613970A1/en
Application granted granted Critical
Publication of CA2613970C publication Critical patent/CA2613970C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2613970A 2005-07-08 2006-07-05 Chimeric vaccine for haemophilus influenzae-induced disease Expired - Fee Related CA2613970C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69764205P 2005-07-08 2005-07-08
US60/697,642 2005-07-08
US80183506P 2006-05-19 2006-05-19
US60/801,835 2006-05-19
PCT/US2006/026183 WO2007008527A2 (en) 2005-07-08 2006-07-05 Chimeric vaccine for haemophilus influenzae-induced disease

Publications (2)

Publication Number Publication Date
CA2613970A1 CA2613970A1 (en) 2007-01-18
CA2613970C true CA2613970C (en) 2015-12-08

Family

ID=37441871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2613970A Expired - Fee Related CA2613970C (en) 2005-07-08 2006-07-05 Chimeric vaccine for haemophilus influenzae-induced disease

Country Status (7)

Country Link
US (3) US7811591B2 (enExample)
EP (2) EP1904519B1 (enExample)
JP (2) JP2009500037A (enExample)
AT (1) ATE488526T1 (enExample)
CA (1) CA2613970C (enExample)
DE (1) DE602006018308D1 (enExample)
WO (1) WO2007008527A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
WO2007008527A2 (en) * 2005-07-08 2007-01-18 Children's Hospital Inc. Chimeric vaccine for haemophilus influenzae-induced disease
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014060385A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2964257B1 (en) 2013-03-08 2024-10-09 Research Institute at Nationwide Children's Hospital Transcutaneous dosage formulation
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3322408B1 (en) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
JP2022504139A (ja) 2018-10-05 2022-01-13 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのｈｍｇｂ１タンパク質誘導体
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity
CN111662384B (zh) * 2020-06-30 2021-04-09 广州百暨基因科技有限公司 抗b7h3抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19005A (en) 1857-12-29 de witt
US697642A (en) 1901-03-09 1902-04-15 Liberty Millet Process of strengthening clay hydraulic pipe, vases, crockery-ware, &c.
US801835A (en) 1905-02-25 1905-10-17 Rudolph H Apelt Ball-bearing.
US1900504A (en) 1930-11-25 1933-03-07 Ingersoll Rand Co Condensing apparatus
JP3429313B2 (ja) * 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン
DE4336530C1 (de) * 1993-10-26 1995-04-13 Max Planck Gesellschaft Rekombinante PilC-Proteine, Verfahren zu ihrer Herstellung und ihre Verwendung
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
AU2004309399B2 (en) 2003-12-23 2012-02-23 Nationwide Children's Hospital, Inc. Haemophilus influenzae type IV pili
WO2007008527A2 (en) * 2005-07-08 2007-01-18 Children's Hospital Inc. Chimeric vaccine for haemophilus influenzae-induced disease

Also Published As

Publication number Publication date
US8263363B2 (en) 2012-09-11
EP1904519A2 (en) 2008-04-02
US20080311110A1 (en) 2008-12-18
WO2007008527A2 (en) 2007-01-18
WO2007008527A3 (en) 2007-03-15
CA2613970A1 (en) 2007-01-18
EP2298794A3 (en) 2011-04-06
US8741304B2 (en) 2014-06-03
JP2010172332A (ja) 2010-08-12
EP2298794A2 (en) 2011-03-23
ATE488526T1 (de) 2010-12-15
JP2009500037A (ja) 2009-01-08
US20110081357A1 (en) 2011-04-07
EP1904519B1 (en) 2010-11-17
US7811591B2 (en) 2010-10-12
US20130064828A1 (en) 2013-03-14
DE602006018308D1 (de) 2010-12-30

Similar Documents

Publication Publication Date Title
US8263363B2 (en) Chimeric vaccine for Haemophilus influenzae-induced disease
US9987343B2 (en) Haemophilus influenzae type IV pili
AU2007206114B2 (en) A novel surface exposed Haemophilus influenzae protein (protein E; pE)
JP2009500037A5 (enExample)
AU2014225330B2 (en) Transcutaneous dosage formulation
US20140199350A1 (en) Chimeric topical vaccine for haemophilus influenzae-induced disease
ES2356077T3 (es) Vacuna quimérica para una enfermedad inducida por haemophilus influenzae.
AU2012203017B2 (en) Haemophilus Influenzae Type IV Pili
HK1144438B (en) Haemophilus influenzae type iv pili
MXPA06007164A (es) Vello de haemophilus influenzae tipo iv
HK1094893B (en) Haemophilus influenzae type iv pili

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190705